hCG vs gonadorelin

Side by side

hCG High and gonadorelin Medium are both used to stimulate the reproductive axis, but they enter it at different points and behave completely differently in the body ¹. The table is read from our encyclopedia entries.

Where each one acts

The chain runs hypothalamus to pituitary to gonads. The hypothalamus releases GnRH in pulses; the pituitary answers with LH and FSH; the gonads respond by making testosterone or maturing an egg.

Gonadorelin is synthetic GnRH, so it acts at the first link, on the pituitary. hCG skips both upstream steps: it binds the same receptor as LH on the testes and ovaries, acting as an LH substitute. That difference decides who each can help. Gonadorelin needs a pituitary and gonads that work; hCG needs only gonads that work, which is why it is used when the pituitary signal is missing ¹.

The half-life difference is the whole story

hCG's terminal half-life after subcutaneous injection is about 29 hours, with an initial phase of 4.5 hours after intravenous dosing, taken from the recombinant product's label ¹. Gonadorelin's is measured in minutes: 2.4 minutes after an intravenous bolus, 5.5 to 8 minutes in the rapid phase after infusion, longer in kidney failure ¹.

That is not a detail; it is the reason the two drugs are given in completely different ways. A long-acting LH substitute can be injected every few days and still work. A GnRH analogue that disappears in minutes has to be delivered in pulses by a pump to imitate the hypothalamus. And if GnRH is given continuously instead, the pituitary desensitises and shuts down, which is the mechanism behind GnRH agonist drugs used to suppress hormones in prostate cancer and endometriosis. Our guide to receptor desensitisation covers that effect.

What hCG is used for, and what the evidence shows

hCG products are FDA-approved for prepubertal cryptorchidism, selected cases of male hypogonadotropic hypogonadism and ovulation induction after gonadotropin pretreatment; the recombinant product Ovidrel is approved for final follicular maturation in assisted reproduction ¹.

Its best-known off-label use is alongside testosterone therapy. In healthy men given testosterone enanthate 200 mg weekly, testosterone alone cut LH and FSH to 5% and 3% of baseline and testicular testosterone by 94%, while adding hCG every other day preserved intratesticular testosterone in a dose-dependent way (randomised trial) ². A retrospective review of hypogonadal men on testosterone with 500 IU hCG every other day found semen parameters unchanged over a mean 6.2 months (retrospective study) ³. In men with azoospermia after steroid use or of unknown cause, hCG with FSH has restored sperm production in small series (case reports and case series) ^{4 5}.

In IVF, hCG is the standard trigger, and the comparison with a GnRH agonist trigger shows the trade-off: a 2014 review found the agonist trigger cut ovarian hyperstimulation syndrome substantially but lowered live births in fresh cycles (review of trials) ⁶.

What gonadorelin was used for

Two human gonadorelin products were FDA-approved, Factrel in 1982 and Lutrepulse in 1989, and both are listed as discontinued; gonadorelin injections remain approved for cattle ¹. Its clinical use was pulsatile pump treatment. In women with hypothalamic amenorrhea given intravenous pulses, ovulation occurred in 91% and 96% of two groups (human study) ⁷. In men with hypogonadism pumped 7 to 15 µg every 90 minutes and followed for about 19 months, LH, FSH and testosterone rose and sperm appeared in 73.3% (human study) ⁸. In a non-randomised comparison in azoospermic men with congenital hypogonadism, sperm appeared sooner on the pump than on injections, a median of 6 against 14 months (non-randomised comparison) ⁹.

Note what that evidence is not. It is pump treatment in people with a specific hormone deficiency, supervised by specialists. It is not a case for injecting small doses of gonadorelin alongside testosterone, which is how the compound is often sold now; our gonadorelin entry records what has been studied.

The question most people are actually asking

Most searches comparing these two come from men on testosterone therapy who want to preserve testicular function or fertility, and who have been offered gonadorelin as an alternative to hCG. On the evidence, the two are not equivalent for that purpose.

hCG has direct evidence in exactly that situation: a randomised trial measuring intratesticular testosterone in men on testosterone ². Gonadorelin's human evidence is for pulsatile pump delivery in hormone-deficient patients ^{7 8}, and its half-life of minutes means an injection once or twice a day is not reproducing the pulses those studies used ¹. We found no trial of intermittent subcutaneous gonadorelin alongside testosterone therapy. Anyone being offered it as a substitute should ask what evidence supports that specific use.

Safety and status

hCG is approved, which means a label with warnings, contraindications and monitoring. Its risks in fertility treatment centre on ovarian hyperstimulation syndrome, which is why the agonist-trigger comparison above matters ⁶. Gonadorelin's rare reactions include allergic responses documented in pump patients, and it no longer has an approved human product in the US ¹.

Both are prohibited in sport under WADA's S2.2.1, in the 2026 and 2027 Lists ¹. Our WADA hub lists each.

Questions to ask a doctor

• Is my problem at the pituitary or the gonads? That decides which drug could work at all.
• If gonadorelin is being proposed, what delivery schedule, and what evidence supports it?
• If fertility is the goal, is a semen analysis being used to measure whether it is working?
• Am I subject to anti-doping rules?

How the differences add up (as of October 3, 2026)

hCG is an approved, long-acting LH substitute with direct evidence for preserving testicular function during testosterone therapy and an established role in fertility treatment. Gonadorelin is synthetic GnRH with a half-life of minutes whose human evidence comes from pulsatile pump treatment in deficiency states, and whose US human products are discontinued. They act at different points on the same axis, and the schedules that make each work are not interchangeable.

Frequently asked questions

What is the difference between hCG and gonadorelin?

hCG acts directly on the gonads as an LH substitute. Gonadorelin is synthetic GnRH and acts on the pituitary, a step earlier.

Is gonadorelin as good as hCG on testosterone therapy?

We found no trial of intermittent gonadorelin alongside testosterone. hCG has a randomised trial measuring intratesticular testosterone in that exact situation.

Why does gonadorelin need a pump?

Its half-life is minutes, and the pituitary responds to pulses; continuous exposure desensitises it instead.

Is gonadorelin FDA-approved?

Both US human products, Factrel and Lutrepulse, are listed as discontinued. Gonadorelin injections remain approved for cattle.

Are hCG and gonadorelin banned in sport?

Yes, both are prohibited under WADA's section S2.2.1 on the 2026 and 2027 Lists.

Related on Grey Peptides

• hCG
• Gonadorelin
• Kisspeptin vs gonadorelin

Sources

1. Grey Peptides dataset records for hCG (Pregnyl, Novarel, generic chorionic gonadotropin and recombinant Ovidrel, FDA-approved; terminal half-life 29 ± 6 hours after subcutaneous injection from the Ovidrel label) and gonadorelin (Factrel, NDA 018123, 1982 and Lutrepulse, NDA 019687, 1989, both discontinued; half-life 2.4 minutes after an IV bolus, 5.5 to 8 minutes in the rapid phase after infusion), WADA S2.2.1 for both; read October 3, 2026.
2. Coviello, A. D., et al. (2005). Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab, 90(5), 2595-602. PMID: 15713727
3. Hsieh, T. C., et al. (2013). Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol, 189(2), 647-50. PMID: 23260550
4. Menon, D. K. (2003). Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril, 79 Suppl 3, 1659-61. PMID: 12801577
5. Kobori, Y., et al. (2015). Hormonal therapy (hCG and rhFSH) for infertile men with adult-onset idiopathic hypogonadotropic hypogonadism. Syst Biol Reprod Med, 61(2), 110-2. PMID: 25518839
6. Youssef, M. A., et al. (2014). Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev, 2014(10), CD008046. PMID: 25358904
7. Santoro, N. (1990). Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. Am J Obstet Gynecol, 163(5 Pt 2), 1759-64. PMID: 2122733
8. Niu, Y. H., et al. (2024). [Effect and safety of pulsatile GnRH therapy for male congenital hypogonadotropic hypogonadism]. Zhonghua Nan Ke Xue, 30(5), 404-409. PMID: 39210488
9. Zhang, L., et al. (2019). The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. Am J Mens Health, 13(1), 1557988318818280. PMID: 30569789

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.